Company intelligence / Profile preview

Ignyte Bio

San Francisco, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Ignyte Bio is a biotechnology company builder and investor that focuses on developing optimized biologics for established therapeutic pathways. Founded by the leadership of Fairmount Funds, the company identifies validated drug targets and builds dedicated biotechnology entities to advance improved therapies, often utilizing antibody engineering through its partner, Paragon Therapeutics. Its portfolio includes prominent clinical-stage companies such as Viridian Therapeutics, Apogee Therapeutics, and Dianthus Therapeutics.

Therapeutic areas: HematologyImmunologyEndocrinologyNeurologyDermatologyPulmonology
Modalities: Monoclonal antibody
Industry: Investors

Partnerships

Fairmount Funds ManagementParagon Therapeutics

Beyond the preview

Go deeper on Ignyte Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ignyte Bio.

Explore the full profile